Biomarkers in Blood Samples From Young Patients With Newly Diagnosed Brain Tumors Undergoing Standard Radiation Therapy and Chemotherapy

• Status: Withdrawn
• Trial end date: 2017-08-24
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Studying samples of blood in the laboratory from patients receiving radiation therapy and chemotherapy may help doctors learn more about the effects of this treatment on cells. It may also help doctors understand how well patients respond to treatment.

PURPOSE: This research study is studying biomarkers in blood samples from young patients with newly diagnosed brain tumors undergoing standard radiation therapy and chemotherapy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pediatric Brain Tumor Consortium
• Collaborator: National Cancer Institute (NCI)

Criteria

DISEASE CHARACTERISTICS:

• Meets 1 of the following criteria:

• Histologically confirmed posterior fossa tumor

• Newly diagnosed disease

• Medulloblastoma OR non-medulloblastoma (pilocytic astrocytoma, ependymoma, atypical rhabdoid tumor, or others)

• Scheduled to undergo craniotomy and tumor resection

• Chiari malformation

• Requires craniectomy for decompression

• No secondary decompression

PATIENT CHARACTERISTICS:

• No unexplained febrile illness

• No active infection

• No autoimmune disorders such as inflammatory bowel disease, juvenile rheumatoid arthritis, or systemic lupus erythematosus

• No other immunosuppressive disorders (e.g., HIV infection)

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics